Key facts
- This page summarizes Adam S. Mostafa's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Feb 2024, 17:10.
Adam S. Mostafa - 13 Feb 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- XFOR
- Reported as of
- 13 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Feb 2024, 17:10:00 UTC
- Prior SEC filing
- 12 Feb 2024
- Next SEC filing
- 11 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paula Ragan, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adam S. Mostafa filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 16 Feb 2024.
Change
- Previous filing in this sequence was filed on 12 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XFOR
transaction
Derivative
Stock Appreciation Right
Award
- Transaction value
- $0
- Shares
- +523,414
- Change %
- Price
- $0.000000
- Shares after
- 523,414
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 523,414
- Exercise price
- $0.9210
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.